(Total Views: 610)
Posted On: 08/29/2025 5:20:03 PM
Post# of 156758
Former HC Wainwright & Co. analyst Swayampakula Ramakanth, Ph.D. previously provided coverage on Cytodyn (CYDY). He downgraded the stock in July 2020 and reiterated a "Buy" rating on several prior occasions in 2019 and 2020.
According to HC Wainwright's website, Dr. Ramakanth is a former Managing Director of Equity Research who focused on the healthcare sector. He is no longer listed as a current analyst for the firm. His analyst profile at HC Wainwright noted that his research covered companies in oncology, wound health, and medical devices.
per Google/AI
According to HC Wainwright's website, Dr. Ramakanth is a former Managing Director of Equity Research who focused on the healthcare sector. He is no longer listed as a current analyst for the firm. His analyst profile at HC Wainwright noted that his research covered companies in oncology, wound health, and medical devices.
per Google/AI
(1)
(0)
